Search Results - "Gordon, Mark F"

Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review by Tang, Eugene Y H, Harrison, Stephanie L, Errington, Linda, Gordon, Mark F, Visser, Pieter Jelle, Novak, Gerald, Dufouil, Carole, Brayne, Carol, Robinson, Louise, Launer, Lenore J, Stephan, Blossom C M

“…Accurate identification of individuals at high risk of dementia influences clinical care, inclusion criteria for clinical trials and development of…”
Get full text

FDG PET in the differential diagnosis of parkinsonian disorders by Eckert, Thomas, Barnes, Anna, Dhawan, Vijay, Frucht, Steve, Gordon, Mark F., Feigin, Andrew S., Eidelberg, D.

“…The differential diagnosis of parkinsonian disorders can be challenging, especially early in the disease course. PET imaging with [ 18F]-fluorodeoxyglucose…”
Get full text

Intramuscular Injection of Botulinum Toxin for the Treatment of Wrist and Finger Spasticity after a Stroke by Brashear, Allison, Gordon, Mark F, Elovic, Elie, Kassicieh, V. Daniel, Marciniak, Christina, Do, Mai, Lee, Chia-Ho, Jenkins, Stephen, Turkel, Catherine

“…Intramuscular injection of botulinum toxin type A has been used to treat patients with spasticity after a stroke, but its efficacy remains uncertain. In this…”
Get full text

Lrrk2 and Lewy body disease by Ross, Owen A., Toft, Mathias, Whittle, Andrew J., Johnson, Joseph L., Papapetropoulos, Spiridon, Mash, Deborah C., Litvan, Irene, Gordon, Mark F., Wszolek, Zbigniew K., Farrer, Matthew J., Dickson, Dennis W.

“…Objective The Lrrk2 kinase domain G2019S substitution is the most common genetic basis of familial and sporadic parkinsonism. Patients harboring the G2019S…”
Get full text

Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials by Kinnunen, Kirsi M, Mullin, Ariana P, Pustina, Dorian, Turner, Emily C, Burton, Jackson, Gordon, Mark F, Scahill, Rachael I, Gantman, Emily C, Noble, Simon, Romero, Klaus, Georgiou-Karistianis, Nellie, Schwarz, Adam J

“…Volumetric magnetic resonance imaging (vMRI) has been widely studied in Huntington's disease (HD) and is commonly used to assess treatment effects on brain…”
Get full text

Formation of neutralizing antibodies in patients receiving botulinum toxin type a for treatment of poststroke spasticity: A pooled-data analysis of three clinical trials by Yablon, Stuart A., MD, Brashear, Allison, MD, Gordon, Mark F., MD, Elovic, Elie P., MD, Turkel, Catherine C., PharmD MBA, Daggett, Simon, BS, Liu, Jingyu, PhD, Brin, Mitchell F., MD

“…Abstract Objective: The purpose of this study was to investigate the incidence of neutralizing antibody (NAb) formation in patients with poststroke spasticity…”
Get full text

Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study by Grachev, Igor D., Meyer, Philipp M., Becker, Georg A., Bronzel, Marcus, Marsteller, Doug, Pastino, Gina, Voges, Ole, Rabinovich, Laura, Knebel, Helena, Zientek, Franziska, Rullmann, Michael, Sattler, Bernhard, Patt, Marianne, Gerhards, Thilo, Strauss, Maria, Kluge, Andreas, Brust, Peter, Savola, Juha-Matti, Gordon, Mark F., Geva, Michal, Hesse, Swen, Barthel, Henryk, Hayden, Michael R., Sabri, Osama

“…Purpose Pridopidine is an investigational drug for Huntington disease (HD). Pridopidine was originally thought to act as a dopamine stabilizer. However,…”
Get full text

Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource by Perera, Gayan, Pedersen, Lars, Ansel, David, Alexander, Myriam, Arrighi, H. Michael, Avillach, Paul, Foskett, Nadia, Gini, Rosa, Gordon, Mark F., Gungabissoon, Usha, Mayer, Miguel-Angel, Novak, Gerald, Rijnbeek, Peter, Trifirò, Gianluca, van der Lei, Johan, Visser, Pieter J., Stewart, Robert

“…The European Medical Information Framework consortium has assembled electronic health record (EHR) databases for dementia research. We calculated dementia…”
Get full text

Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review by Kinnunen, Kirsi M, Schwarz, Adam J, Turner, Emily C, Pustina, Dorian, Gantman, Emily C, Gordon, Mark F, Joules, Richard, Mullin, Ariana P, Scahill, Rachael I, Georgiou-Karistianis, Nellie

“…Huntington's disease (HD) is an autosomal-dominant inherited neurodegenerative disorder that is caused by expansion of a CAG-repeat tract in the huntingtin…”
Get full text

Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study by Legdeur, Nienke, Badissi, Maryam, Carter, Stephen F, de Crom, Sophie, van de Kreeke, Aleid, Vreeswijk, Ralph, Trappenburg, Marijke C, Oudega, Mardien L, Koek, Huiberdina L, van Campen, Jos P, Keijsers, Carolina J P W, Amadi, Chinenye, Hinz, Rainer, Gordon, Mark F, Novak, Gerald, Podhorna, Jana, Serné, Erik, Verbraak, Frank, Yaqub, Maqsood, Hillebrand, Arjan, Griffa, Alessandra, Pendleton, Neil, Kramer, Sophia E, Teunissen, Charlotte E, Lammertsma, Adriaan, Barkhof, Frederik, van Berckel, Bart N M, Scheltens, Philip, Muller, Majon, Maier, Andrea B, Herholz, Karl, Visser, Pieter Jelle

“…The oldest-old (subjects aged 90 years and older) population represents the fastest growing segment of society and shows a high dementia prevalence rate of up…”
Get full text

Importance and hurdles to drug discovery for neurological disease by Berger, Joseph R., Choi, Dennis, Kaminski, Henry J., Gordon, Mark F., Hurko, Orest, D'Cruz, O'Neill, Pleasure, Samuel J., Feldman, Eva L.

“…This is a critical time in neurotherapeutics. The prevalence of neurological disease, such as dementia, stroke, and peripheral neuropathy, is large and growing…”
Get full text

An Examination of Executive Dysfunction Associated with Frontostriatal Circuitry in Parkinson's Disease by Zgaljardic, Dennis J., Borod, Joan C., Foldi, Nancy S., Mattis, Paul J., Gordon, Mark F., Feigin, Andrew, Eidelberg, David

“…Parkinson's disease (PD) is a neurodegenerative movement disorder presenting with subcortical pathology and characterized by motor deficits. However, as is…”
Get full text

Relationship between self-reported apathy and executive dysfunction in nondemented patients with parkinson disease by ZGALJARDIC, Dennis J, BOROD, Joan C, FOLDI, Nancy S, ROCCO, Mary, MATTIS, Paul J, GORDON, Mark F, FEIGIN, Andrew S, EIDELBERG, David

“…The prevalence of apathy was assessed across select cognitive and psychiatric variables in 32 nondemented patients with Parkinson disease (PD) and 29…”
Get full text

CONSORTIA DRIVEN APPROACH TO ADDRESSING CLINICAL MEANINGFULNESS IN EARLY AD by Ropacki, Michael T, Hannesdottir, Kristin, Hendrix, Suzanne, Gordon, Mark F, Stephenson, Diane, Coons, Stephen J, Stern, Robert A

Get full text

Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease by Mentis, Marc J., Delalot, Dominique, Naqvi, Hassan, Gordon, Mark F., Gudesblatt, Mark, Edwards, Christine, Donatelli, Luke, Dhawan, Vijay, Eidelberg, David

“…Anticholinesterase (AChE) drugs are being prescribed off label for nonmotor symptoms in Parkinson's disease (PD). Theoretically, these drugs can impair motor…”
Get full text

Toxin and drug-induced myoclonus by Gordon, Mark F

Get more information

Botulinum Toxin for Spasticity after Stroke by Landau, William M

“…To the Editor: The design of the study by Brashear et al. of botulinum toxin for stroke (Aug. 8 issue) 1 fails to meet the claim of a “double-blind,…”
Get full text

MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study by Ten Kate, Mara, Redolfi, Alberto, Peira, Enrico, Bos, Isabelle, Vos, Stephanie J, Vandenberghe, Rik, Gabel, Silvy, Schaeverbeke, Jolien, Scheltens, Philip, Blin, Olivier, Richardson, Jill C, Bordet, Regis, Wallin, Anders, Eckerstrom, Carl, Molinuevo, José Luis, Engelborghs, Sebastiaan, Van Broeckhoven, Christine, Martinez-Lage, Pablo, Popp, Julius, Tsolaki, Magdalini, Verhey, Frans R J, Baird, Alison L, Legido-Quigley, Cristina, Bertram, Lars, Dobricic, Valerija, Zetterberg, Henrik, Lovestone, Simon, Streffer, Johannes, Bianchetti, Silvia, Novak, Gerald P, Revillard, Jerome, Gordon, Mark F, Xie, Zhiyong, Wottschel, Viktor, Frisoni, Giovanni, Visser, Pieter Jelle, Barkhof, Frederik

“…With the shift of research focus towards the pre-dementia stage of Alzheimer's disease (AD), there is an urgent need for reliable, non-invasive biomarkers to…”
Get full text

O1‐05‐03: CONSORTIA DRIVEN APPROACH TO ADDRESSING CLINICAL MEANINGFULNESS IN EARLY AD by Ropacki, Michael T., Hannesdottir, Kristin, Hendrix, Suzanne, Gordon, Mark F., Stephenson, Diane, Coons, Stephen J., Stern, Robert A.

Get full text

The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson's disease: a randomized, double-blind, double-dummy, parallel-group study by Wang, Ying, Sun, Shenggang, Zhu, Suiqiang, Liu, Chunfeng, Liu, Yiming, Di, Qing, Shang, Huifang, Ren, Yan, Lu, Changhong, Gordon, Mark Forrest, Juhel, Nolwenn, Chen, Shengdi

“…To evaluate the non-inferiority of pramipexole extended-release (ER) versus immediate-release (IR) in Chinese patients with Parkinson's disease (PD) in a…”
Get full text